KOD

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Kodiak Sciences (KOD) is back in focus after reporting positive topline Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy, supporting a potential multi indication filing and sharpening attention on its late stage pipeline. See our latest analysis for Kodiak Sciences. The latest share price of US$43.68 comes after a 90 day share price return of 89.58% and a very large 1 year total shareholder return, as fresh Phase 3 data and recent conference presentations keep momentum building despite ongoing quarterly losses. If this kind of clinical news has your attention, it can be helpful to see what else is moving in the sector with the 35 healthcare AI stocks With shares up sharply over the past year, Kodiak now trades at US$43.68, below an average analyst price target of about US$56. So is the market still underestimating the late stage pipeline, or already pricing in future growth? Kodiak trades on a P/B of 17.2x, well above both its direct peers at 3.9x and the broader US Biotechs industry at 2.5x. P/B compares a company’s market value with its book value. A higher multiple often reflects strong expectations for future assets and returns that are not yet visible in current financials. For Kodiak, this is sitting alongside minimal reported revenue, ongoing losses of $229.967m and a clinical stage pipeline that is still moving through trials. With forecasts pointing to no revenue next year and continued losses over the next 3 years, the market is clearly paying up relative to book value, even as Kodiak is flagged as trading 87.2% below the SWS DCF estimate of future cash flow value at $342.57. Compared with both peer and industry P/B levels, the current 17.2x looks materially richer, which places more weight on how investors view the late stage retinal portfolio than on present balance sheet metrics. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 17.2x (OVERVALUED) However, there are clear pressure points, including continued quarterly losses of $229.967m and a complete lack of reported revenue, which could challenge sentiment. Find out about the key risks to this Kodiak Sciences narrative. The P/B of 17.2x paints Kodiak as expensive relative to peers, yet our...

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key clinical readouts and our first planned regulatory submission," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The recent positive Phase 3 GLOW2 results for Zenkuda reinforce the strength of our ABC Platform and position us to move forward on our first multi-indication BLA submission. At the same time, we are making meaningful progress across our late-stage portfolio, including continued advancement of KSI-101 and KSI-501, and we eagerly anticipate the September readout for DAYBREAK Phase 3 in wet AMD and the December readout for PEAK Phase 3 in MESI. This year is a defining period for Kodiak, with important opportunities for further clinical validation, regulatory progress and continued evolution of our identity as a vision sciences company," continued Dr. Perlroth. Recent Business Highlights Zenkuda (tarcocimab tedromer) — Accelerating Toward BLA Submission On March 26, 2026, Kodiak announced positive topline results in GLOW2, the second Phase 3 study of Zenkuda (tarcocimab tedromer) in diabetic retinopathy (DR), demonstrating superiority over sham. Zenkuda demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001). Zenkuda also demonstrated superiority to sham with an 85% risk reduction in the key secondary endpoint of development of sight threatening complications (2.4% with Zenkuda vs 15.8% with sham, p=0.0001) and with a ≥3-step improvement in DRSS (13.7% with Zenkuda vs 0% with sham, p<0.0001). Zenkuda showed strong efficacy independent of GLP-1 receptor agonist use, supporting its profile in a real-world diabetic population. Zenkuda was well tolerated with no instances of intraocular inflammation, retinal vasculitis or occlusive retinal vasculitis, and a low cataract adverse event rate (2% per arm). Combined with the previously reported Phase 3 study readouts (GLOW1, BEACON and DAYLIGHT), Zenkuda now has a multi-indication BLA-ready profile. Phase 3 DAYBREAK Study — Topline Data Expected September 202...

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies. The ABCD PlatformTM, an evolution of Kodiak's ABC platform to include conjugation of small molecules and other drugs, continues to advance as a versatile system for targeted, multi-modal drug development in retina and glaucoma optic neuropathy. PALO ALTO, Calif., May 1, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced it will present pipeline advances and clinical results of KSI-101 in a cohort of tertiary care MESI patients at the 2026 American Uveitis Society (AUS) Meeting and the 2026 Association for Research in Vision and Ophthalmology (ARVO) Meeting. "Results from a tertiary care uveitis practice were highly consistent with those observed in the U.S. Phase 1b APEX study," said Pablo Velazquez-Martin, M.D., Chief Medical Officer of Kodiak Sciences. "These findings add to the growing body of evidence supporting KSI-101 in MESI and provide early support for its applicability across diverse patient populations globally, irrespective of the underlying cause of the inflammation and the severity of the disease." "Our presentations at the American Uveitis Society and the Association for Research in Vision and Ophthalmology showcase both the clinical progress of KSI-101 and the continued advancement of our pipeline molecules and pipeline science," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We look forward to engaging with colleagues at these conferences as we continue to deepen our science and grow our team." Presentations at American Uveitis Society –Saturday, May 2, 2026, in Aurora, Colorado Format: Oral presentation Presentation Title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Week 24 Results from the...

A month has gone by since the last earnings report for Kodiak Sciences Inc. (KOD). Shares have added about 2% in that time frame, underperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Kodiak Sciences due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus Kodiak reported fourth-quarter 2025 loss of $1.04 per share, wider than the Zacks Consensus Estimate of $1.02 per share. The company had incurred a loss of 84 cents per share in the year-ago quarter. The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues. KOD's Q4 Results in Detail Research and development expenses were $45.5 million in the reported quarter, up 43.1% year over year. The rise was mainly due to increased clinical activities associated with ongoing clinical studies and higher stock-based compensation expenses. General and administrative expenses were $12 million, down 17% year over year, primarily due to lower non-cash stock-based compensation expenses and additional sublease income offsetting costs. As of Dec. 31, 2025, Kodiak had cash, cash equivalents and marketable securities worth $209.9 million compared with $72 million as of Sept. 30, 2025. Full-Year 2025 Results For full-year 2025, the company incurred a net loss of $4.32 per share, wider than a loss of $3.35 per share incurred in 2024. In the past month, investors have witnessed a downward trend in estimates revision. The consensus estimate has shifted -7.58% due to these changes. Currently, Kodiak Sciences has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for value investors. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Kodiak Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stoc...

All three major US stock indexes were up in midday trading on Wednesday as traders awaited President

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline programs that together reinforce the company's differentiated molecules, platform and long term growth strategy," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The GLOW2 Phase 3 study delivered strong topline results showing meaningful efficacy, safety and durability of Zenkuda (tarcocimab tedromer) in diabetic retinopathy. These results represent a significant validation of the company's ABC platform, and we intend to move on an accelerated timeline toward a multi-indication Biologics License Application (BLA) submission for Zenkuda." We have also completed enrollment in the Phase 3 DAYBREAK study of both Zenkuda and KSI-501 in patients with neovascular age-related macular degeneration (wet AMD), with approximately 690 subjects enrolled. Topline data is expected in September 2026. We are also rapidly advancing KSI-101 with enrollment progressing well in the Phase 3 PEAK and PINNACLE studies. Topline results from PEAK are expected in 4Q 2026 and for PINNACLE in 2Q 2027. KSI-101 demonstrated compelling data in the Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI). Final Phase 1b APEX data showed rapid and robust improvements in both vision and retinal anatomy, including high rates of ≥15-letter BCVA gains, early and sustained retinal drying, and encouraging durability. These findings support continued development and highlight the breadth of Kodiak's platform beyond anti-VEGF therapies into inflammatory retinal diseases. Beyond our lead programs, we continue to expand a diversified pipeline of bispecific antibody candidates, including KSI-102 and KSI-103, targeting key inflammatory pathways, as well as retina duet programs in glaucoma and geographic atrophy. Our duet programs, built on the ABC platform, reflect a strategy to address a broad range of high prevalence retinal diseases with differentiated, multi-targeted approaches. In parallel, we have made tremendous progress with our digital health and artificial intelligence capabiliti...

Kodiak Sciences Inc. (NASDAQ:KOD) is one of the 10 Stocks Investors Dominating the Market Today. Kodiak Sciences soared by 74.77 percent on Thursday to finish at $39.76 apiece, as investors took heart from the strong results of its clinical study for its diabetic retinopathy treatment. In an updated report, Kodiak Sciences Inc. (NASDAQ:KOD) said that 62.5 percent of the enrolled patients in the GLOW clinical trial achieved a more than 2-step improvement in diabetic retinopathy severity score for those who took Zenkuda, as compared with 3.3 percent of the sham group. Photo by Nataliya Vaitkevich on Pexels The patients were randomized to receive either a sham injection or Zenkuda via intravitreal injection at progressively extended intervals. Zenkuda also showed an 85-percent risk reduction in sight-threatening complications. The drug candidate also demonstrated favorable safety and was well tolerated in the study, with a 0 percent intraocular inflammation rate and a 2.3 percent cataract adverse event rate, versus 1.6 percent with sham. "We are very pleased to see that GLOW2 demonstrated a high degree of internal consistency across all datapoints. Importantly, GLOW2 also demonstrated strong external consistency when contextualized with GLOW1. Taken together, the combined GLOW1 and GLOW2 data package speaks volumes about the robustness of the data and the operational approach the team brought to the conduct of both studies," Kodiak Sciences Inc. (NASDAQ:KOD) Chief Medical Officer J. Pablo Velazquez-Martin said. While we acknowledge the potential of KOD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years. Disclosure: None. Follow Insider Monkey on Google News.

(Updates with recent stock price movement in the headline and first paragraph.) Kodiak Sciences (

PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI). Presentation title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Phase 1b APEX Study in Patients with Macular Edema Secondary to Inflammation (MESI) Time: 5:15 PM EST The presentation will be posted at the start of the event on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/. "This year's Angiogenesis meeting marks the first presentation of end-of-study results from the APEX study for KSI-101. These final data continue to demonstrate robust anatomic and visual improvements in patients with MESI, regardless of the underlying etiology or location of inflammation, further supporting the clinical efficacy and safety profile of KSI-101 observed to date. With PEAK and PINNACLE Phase 3 studies actively enrolling, these final results strengthen our confidence in KSI-101's potential to become a safe, first-line unifying therapy for all causes of MESI," said Victor Perlroth, M.D., Chairman and CEO of Kodiak Sciences. About KSI-101 KSI-101 is a novel, potent and high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. We are developing KSI-101 for patients with macular edema (retinal fluid) secondary to inflammation (MESI). MESI is a heterogenous group of diseases that clinically present with macular edema and visual impairment which are caused by a common pathophysiology–inflammation and blood retinal barrier disruption. The clinical presentation of retinal fluid and visual impairment is a mainstay in these patients, irrespective of the location of the inflammation inside of the eye (anterior, intermediate, posterior or all intraocular compartments) or the specific etiology (defined autoimmune associated, idiopathic, post-procedural, or inflammatory choroidal neovascul...

PALO ALTO, Calif., Nov. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended September 30, 2025. "Kodiak Sciences has entered a period of strong, sustained momentum driven by compelling clinical data, accelerated execution and growing external enthusiasm...across all three of our late-stage programs," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "Looking ahead, we expect this momentum to continue building as we enter an action-packed 2026 with all three of our Phase 3 assets on track for Phase 3 topline data readouts as well as our first planned BLA filing. On top of our late-stage programs, Kodiak's early-stage pipeline is also advancing with increasing speed and conviction, positioning Kodiak for sustained scientific and pipeline leadership globally," continued Dr. Perlroth. Recent Business Highlights Announced follow-up data through week 20 from the Phase 1b APEX study of KSI-101 in patients with macular edema secondary to inflammation (MESI) Meaningful vision gains were rapidly achieved as early as week 4 and showed continued improvement in best corrected visual acuity (BCVA) through week 20, with more than half of patients achieving improvement of 3-lines or more on the eye chart (≥15 letter gain). ≥90% of patients in the top two dose levels achieved and sustained real dryness of the retina, as demonstrated by absence of intraretinal fluid (IRF) as well as subretinal fluid (SRF), key markers of disease activity. The Phase 3 PEAK and PINNACLE studies of KSI-101 are enrolling at a faster-than-expected pace, evaluating the top two dose levels (5 mg and 10 mg) in patients with MESI. Validation from the scientific community for the mechanism of action behind KSI-101 At the recent American Academy of Ophthalmology (AAO) meetings, intraocular interleukin-6 inhibition was shown in Phase 3 clinical trials to deliver a meaningful improvement in vision and anatomy in patients with uveitic macular edema, a key component of MESI. Local IL-6 inhibition also appeared to be well tolerated in these trials. Data appear to highlight a significant opportunity for KSI-101, a potent inhibitor of interleukin-6 that layers on potent inhibition of VEGF, to drive a stronger clinical effect. Completed enrollment in the Phase 3 DAYBREAK study of both tarco...

Kodiak Sciences (KOD) just shared encouraging Phase 3 clinical trial data at the American Academy of Ophthalmology meetings. The results suggest their IL-6 inhibitor could offer significant vision improvements for patients with uveitic macular edema. See our latest analysis for Kodiak Sciences. Kodiak Sciences has been catching investors’ attention, as its latest clinical progress seems to have sparked a wave of optimism. The stock’s share price has surged with a 65% return over the past month and is now up 128% year-to-date. The one-year total shareholder return stands at a remarkable 286%. Momentum is clearly building following this encouraging Phase 3 news and ongoing advancements in their pipeline. If you’re interested in spotting more high-upside biotechnology and pharma names making similar moves, check out See the full list for free. With the stock soaring and optimism reaching new highs, the question now is whether Kodiak Sciences is genuinely undervalued or if the market has already priced in all of its future growth potential. Is there still a buying opportunity here? Kodiak Sciences is trading at a price-to-book ratio of 14.7x, which is notably higher than its industry peers and the broader biotech sector. With the last close at $19.63, the company’s valuation stands well above conventional comparables on this metric. The price-to-book ratio compares a company’s market value to its book value, providing insight into whether the stock is valued higher than the assets on its balance sheet. For early-stage or unprofitable biotech firms, this ratio can reflect investor expectations around future breakthroughs or pipeline successes, rather than current earnings. In Kodiak Sciences’ case, a 14.7x price-to-book ratio is significantly more expensive than peers, with the US Biotechs industry averaging 2.5x. The peer group average is even negative at -4.6x, emphasizing the premium investors are paying for Kodiak’s potential. This suggests the market is factoring in ambitious growth scenarios, despite the company’s current unprofitability and lack of revenue. If the market’s high hopes prove warranted, valuation levels could remain elevated, but the industry average shows what “normal” could look like if sentiment changes. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book Ratio of 14.7x (OVERVALUED) Howeve...

PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. "Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial vision for our three late-stage clinical assets –tarcocimab, KSI-501 and KSI-101– underscoring their transformative potential in retinal disease treatment," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The event featured new 12-week data from the KSI-101 APEX Phase 1b study, underscoring the opportunity for KSI-101 to treat patients with macular edema secondary to inflammation (MESI). The webcast also offered scientific, clinical and commercial perspectives and included commentary from two retina opinion leaders Dr. Sumit Sharma and Dr. Charles Wykoff. We encourage you to listen to the webcast and to review the presentation which are both available on the Investors & Media page of our website." Recent Business Highlights and Upcoming Catalysts Tarcocimab – Phase 3 topline data expected in 1Q 2026 (6 months) and 3Q 2026 (12 months) Phase 3 GLOW2 diabetic retinopathy study – topline data on track for 1Q 2026 Phase 3 DAYBREAK wet AMD study – topline data expected 3Q 2026 Completed the manufacturing and release of BLA-facing commercial-scale batches in Kodiak's URSUS facility KSI-501 – Phase 3 topline data expected in 3Q 2026 (12 months) Phase 3 DAYBREAK wet AMD study – topline data expected 3Q 2026 Planning for second Phase 3 study with possible start by 1Q 2026 KSI-101 – Phase 3 topline data expected in 4Q 2026 - 1Q2027 (18 months) Phase 1b multiple dose clinical trial data in patients with Macular Edema Secondary to Inflammation (MESI) demonstrated that a single dose of KSI-101 provided rapid and meaningful anatomical gains by Week 1, with corresponding visual acuity gains. Further anatomical and visual improvement were achieved with continued dosing, with more than 90% of patients in the study achieving dryness by week 8 (the effect of two doses of KSI-101), as evidenced by absence of both intra- and sub-retinal fluid. The APEX MESI data in patients who completed Week 12 also showed that half of the patients achieved a ≥15 letter gain, with an apparent additional benefit in the top two dose levels. Importantly, KSI-101 was well tolerated. Phase 3...